/ETX.L
ETX.L Stock - E-therapeutics Plc
Healthcare|BiotechnologyLSE
$9.00-6.74%
$0.65 (-6.74%) • May 8
56
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.6
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $9.90
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for ETX.L
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$8.91 – $9.09
TARGET (TP)$10.35
STOP LOSS$8.28
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.46
52W High$24.00
52W Low$9.00
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|
| Revenue | $318,000 | $475,000 | $477,000 | $317,000 | $456,000 |
| Gross Profit | $318,000 | $475,000 | $477,000 | $317,000 | $456,000 |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating Income | $-13,794,000 | $-10,239,000 | $-9,542,000 | $-4,455,000 | $-2,885,000 |
| Net Income | $-11,166,000 | $-8,274,000 | $-8,067,000 | $-3,684,000 | $-2,347,000 |
| Net Margin | -3511.3% | -1741.9% | -1691.2% | -1162.1% | -514.7% |
| EPS | $-0.02 | $-0.02 | $-0.02 | $-0.01 | $-0.01 |
Company Overview
e-Therapeutics plc engages in drug discovery research activities in the United Kingdom. Its computational platform provides in silico screens generate predictions on compounds and/or targets that can have a significant perturbative effect on the biology of interest, captured by its network models, as well as developing RNAi platform for highly specific gene silencing. The company was incorporated in 2001 and is based in London, the United Kingdom.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
ETX.LBeat Rate
0%
Last 0 quarters
Avg Surprise
+0%
EPS vs Estimate
Beats / Misses
0/0
Last 12 quarters
Latest EPS
$-0.01
Q2 2024
EPS Surprise History
Q3 20
No data
Q1 21
No data
Q3 21
No data
Q1 22
No data
Q3 22
No data
Q2 23
No data
Q4 23
No data
Q2 24
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2024 | Oct 24, 2024 | — | — | — | — |
Q2 2024 | Apr 29, 2024 | — | $-0.01 | — | — |
Q4 2023 | Oct 26, 2023 | — | $-0.01 | — | — |
Q2 2023 | May 4, 2023 | — | $-0.01 | — | — |
Q3 2022 | Jul 31, 2022 | — | $-0.01 | — | — |
Q1 2022 | Jan 31, 2022 | — | $-0.01 | — | — |
Q3 2021 | Jul 31, 2021 | — | $-0.01 | — | — |
Q1 2021 | Jan 31, 2021 | — | $-0.00 | — | — |
Q3 2020 | Jul 31, 2020 | — | $-0.01 | — | — |
Q1 2020 | Jan 31, 2020 | — | $-0.00 | — | — |
Q3 2019 | Jul 31, 2019 | — | $-0.00 | — | — |
Q1 2019 | Jan 31, 2019 | — | $-0.01 | — | — |
Q3 2018 | Jul 31, 2018 | — | $-0.01 | — | — |
Q1 2018 | Jan 31, 2018 | — | $-0.01 | — | — |
Q3 2017 | Jul 31, 2017 | — | $-0.01 | — | — |
Q1 2017 | Jan 31, 2017 | — | $-0.02 | — | — |
Q3 2016 | Jul 31, 2016 | — | $-0.03 | — | — |
Q1 2016 | Jan 31, 2016 | — | $-0.02 | — | — |
Q3 2015 | Jul 31, 2015 | — | $-0.02 | — | — |
Q1 2015 | Jan 31, 2015 | — | $-0.01 | — | — |
Latest News
Loading news...
Frequently Asked Questions about ETX.L
What is ETX.L's current stock price?
E-therapeutics Plc (ETX.L) is currently trading at $9.00 per share. The stock has moved -6.74% today.
What is the analyst price target for ETX.L?
No analyst price targets are currently available for this stock.
What sector is E-therapeutics Plc in?
E-therapeutics Plc operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the LSE exchange.
What is ETX.L's market cap?
E-therapeutics Plc has a market capitalization of $0.06 billion, making it a small-cap company.
Does ETX.L pay dividends?
No, E-therapeutics Plc does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorBVX.L
BiVictriX Therapeutics Plc
$10.00
Mkt Cap: $0.8B
C4XD.L
C4X Discovery Holdings plc
$12.00
Mkt Cap: $3.0B
DEST.L
Destiny Pharma plc
$3.00
Mkt Cap: $0.3B
IUG.L
Intelligent Ultrasound Group plc
$12.88
Mkt Cap: $4.3B
MTPH.L
Midatech Pharma plc
$18.00
Mkt Cap: $3.1B
NSCI.L
NetScientific plc
$53.12
Mkt Cap: $1.3B
OKYO.L
OKYO Pharma Limited
$1.40
Mkt Cap: $2.3B
REDX.L
Redx Pharma Plc
$15.00
Mkt Cap: $5.8B
SNG.L
Synairgen plc
$0.95
Mkt Cap: $1.2B
TCF.L
Theracryf Plc
$0.22
Mkt Cap: $0.5B
Explore stocks similar to ETX.L for comparison